Study | Population | Study | Substrate | CXCL13 levels with treatment |
---|---|---|---|---|
Moura et al. (2017) [15] | N = 33. ERA, EstRA Anti-TNF, anti-IL6R | Cohort | Serum by ELISA | No change with: ADA, GOL, ETN or TCZ |
Rinaldi et al.* (2017) [33] | N = 34. EstRA Anti-IL6R | RCT | Serum, method not published | Reduction with anti-IL-6 (TCZ, vobarilizumab) |
Han et al. (2016) [16] | N = 29. EstRA Anti-TNF | Cohort | Serum by ELISA | Reduction with TNF (ADA/ETN) in TNF responders B/L high level associated greater response |
Bugatti et al.* (2016) [34] | N = 205. ERA csDMARD | Cohort | Serum, method not published | B/L high levels predict failure of remission |
Kumagai et al.* (2016) [17] | N = 146. EstRA Anti-TNF | Cohort | Serum by ELISA | Reduction with ADA in ADA responder. Not seen with IFX |
Loza et al.* (2016) [18] | N = 916. ERA Anti-IL6 | Cohort | Serum by ELISA, MSD, Luminex | No change with sirukumab |
Bugatti et al.* (2016) [19] | N = 213. EstRA csDMARD | Cohort | Both, method not published | B/L high levels predict failure of remission |
Greisen et al. (2014) [23] | N = 114. ERA csDMARD, Anti-TNF | Cohort | Serum by ELISA | Correlate with treatment response. B/L high level predict ADA treatment remission |
Bugatti et al.* (2014) [24] | N = 205 csDMARD | Cohort | Serum by ELISA | No change with treatment |
de Jong et al. (2014) [35] | N = 18 Anti-CD20 | Cohort | Serum by Luminex | Reduction with rituximab irrespective of responder status |
El-Sherbiny et al.* (2013) [36] | N = 23 Anti-CD20 | Cohort | Synovial by mRNA qPCR | Reduction with rituximab in rituximab responders |
Taylor et al. (2017) * [37] | N = 65 EstRA JAKi | RCT | Serum, method not published | Reduction with filgotinib. No change with placebo |
Gabay et al. (2016) [38] | N = 356 EstRA Anti-IL6R | RCT | Serum by ELISA | Reduction with sarilumab (p < 0.01) from 2 weeks |
Boyle et al. (2015) [39] | N = 29 EstRA JAKi | RCT | Serum by ELISA | Reduction with tofacitinib. No change with placebo |
Dennis et al. (2014) [40] | N = 198. EstRA Anti-TNF, anti-IL6R | RCT | Serum by ECLA | Low B/L levels associate greater response to ADA High B/L levels associated greater response to TCZ |
Kennedy et al. (2014) [41] | N = 214. EstRa Anti-TNF, antiLTα | RCT | Serum by ELISA & MSD | Reduction with ADA and pateclizumab. |
Herman et al. (2013) [42] | N = 325. EstRa Anti-TNF, anti-IL6 | RCT | Serum, method not published | Reduction with ADA, correlates with ADA response Reduction with TCZ, B/L high levels predict response |
Emu et al. * (2012) [43] | N = 65 antiLTα | RCT | Serum by ELISA | Reduction with pateclizumab |
Rosengren et al. (2011) [44] | N = 24, Anti-CD20 | Cohort | Both by ELISA, mRNA qPCR | Reduction with rituximab at 2 months, which was maintained at 6 months |